USPTO Examiner MCANANY JOHN D - Art Unit 1625

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18411323PYRAZOLO[1,5-a]PYRIDO[4,3-e]PYRIMIDINE-2-CARBOXYLIC ACIDS AS CK2 INHIBITORSJanuary 2024May 2024Allow401NoNo
18408940PYRIDO[4,3-E][1,2,3]TRIAZOLO[1,5-A]PYRIMIDINE AS CK2 INHIBITORSJanuary 2024April 2024Allow301NoNo
18404721IMIDAZO[1,5-a]PYRIDO[4,3-e]PYRIMIDINES AS CK2 INHIBITORSJanuary 2024April 2024Allow401NoNo
18535108MATERIAL AND METHOD FOR TREATING CANCERDecember 2023September 2024Allow911NoNo
18383135HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STINGOctober 2023November 2025Allow2500YesNo
18264939SYNTHESIS OF TIGILANOL TIGLATE AND ANALOGS THEREOFAugust 2023December 2025Allow2800NoNo
18035491SMALL MOLECULE COMPOUND AND USE AND COMPOSITION THEREOFJune 2023October 2025Allow2900YesNo
18257976MACROCYCLIC BRANCHED 3-FLUORO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1June 2023October 2025Allow2800NoNo
18265425PYRIDINYLPYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOFJune 2023October 2025Allow2800YesNo
18265023Heterocyclic Derivatives as P2X7 Receptor AntagonistsJune 2023October 2025Allow2800YesNo
18253572MALT-1 MODULATORSMay 2023September 2025Allow2800YesNo
18138357PROCESS-SCALE SYNTHESIS OF UROLITHIN AApril 2023February 2025Allow2211NoNo
18298256CELL SIGNAL DETECTION AND MODULATION IN DISEASEApril 2023May 2024Abandon1301NoNo
18296215Salt Forms and Solvates of Mcl-1 AntagonistsApril 2023March 2025Allow2300YesNo
18295476Compositions And Methods For The Treatment Of AlopeciaApril 2023June 2025Allow2631YesNo
18187866COMPOSITIONS AND METHODS FOR TREATING CASTRATION-RESISTANT PROSTATE CANCERMarch 2023January 2025Abandon2221NoNo
18186816COMBINATION THERAPY FOR TREATING CANCERMarch 2023July 2025Allow2831YesNo
18182620IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINSMarch 2023November 2025Allow3201NoNo
18115955COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONSMarch 2023September 2024Abandon1811NoNo
18005713HERBICIDAL COMPOUNDSJanuary 2023September 2025Allow3200YesNo
18004628SALTS AND FORMS OF A WEE1 INHIBITORJanuary 2023December 2025Allow3510YesNo
179880622,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDSNovember 2022March 2026Abandon4001NoNo
17982487ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOFNovember 2022June 2024Abandon2010NoNo
17997375CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERSOctober 2022March 2026Abandon4010NoNo
18048719OMEGA MURICHOLIC ACID AS A PREGNANE X RECEPTOR LIGAND FOR TREATING HEPATO-INTESTINAL DISEASESOctober 2022June 2024Abandon2010NoNo
17917593NEW ANTI-MALARIAL AGENTSOctober 2022September 2025Allow3500YesNo
17937977COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USEOctober 2022June 2025Allow3231YesNo
17935961BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA 1 PAMSeptember 2022December 2024Allow2611NoNo
17948251INHIBITION OF PROTEIN AMYLOID AGGREGATION USING FLUORINATED BENZENESULFONAMIDESSeptember 2022December 2024Allow2721YesNo
17899814Synthesis method of lactide by confinement effect catalysis of crystalline porous polymer materialAugust 2022January 2024Allow1710NoNo
17862962PROANGIOGENIC PROTEIN COCKTAILS DELIVERED IN CUSTOM BIOMATERIALS TO REVASCULARIZE ISCHEMIC TISSUEJuly 2022May 2024Allow2210NoNo
17791834Modified Thioxanthone PhotoinitiatorsJuly 2022September 2025Allow3900YesNo
17788680GALECTIN-3 INHIBITING C-GLYCOSIDE KETONES, ETHERS, AND ALCOHOLSJune 2022April 2025Allow3400YesNo
17806695INTRATUMORAL ADMINISTRATION OF ASCORBIC ACID AND QUINONE COMPOUNDS FOR TUMOR TREATMENTJune 2022October 2025Abandon4020NoNo
17836871CONTROLLED-DELIVERY CROMAKALIM PRODRUGSJune 2022June 2025Allow3700YesNo
17781201BIARYL COMPOUND AS PAN-RAF KINASE INHIBITORMay 2022July 2025Abandon3710NoNo
17730565AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONSApril 2022September 2024Allow2811YesNo
17771114BICYCLIC COMPOUND AND USE THEREOFApril 2022March 2025Allow3500YesNo
17766400HETEROCYCLIC COMPOUNDApril 2022March 2025Allow3500NoNo
17629530ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOFJanuary 2022February 2026Allow4920YesNo
17626777CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORSJanuary 2022January 2026Allow4821YesNo
17644486PYRIDYLPYRIDONE COMPOUNDSDecember 2021March 2025Abandon3901NoNo
17546204MATERIAL AND METHOD FOR TREATING CANCERDecember 2021February 2025Allow3820YesYes
17615008Composition for Prevention, Amelioration, or Treatment of CancerNovember 2021June 2025Allow4210YesNo
17512326TREATMENT OF CANCER AND INHIBITION OF METASTASISOctober 2021December 2025Allow5020NoNo
17594577COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTSOctober 2021April 2025Allow4210YesNo
17604322PROCESS FOR PREPARATION OF AXITINIBOctober 2021September 2025Allow4720YesNo
17498256Combinations For Treatment Of NASH/NAFLD And Related DiseasesOctober 2021November 2024Allow3700YesNo
17493397STABLE PARENTERAL DOSAGE FORM OF PYRAZOLONE DERIVATIVEOctober 2021May 2024Abandon3101NoNo
17440705BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAMESeptember 2021March 2025Allow4211YesNo
17422644COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITYJuly 2021June 2025Abandon4701NoNo
17419833INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTSJune 2021March 2025Abandon4401NoNo
17419997IL-17A INHIBITORSJune 2021December 2024Allow4201YesNo
17418034DOMPERIDONE COMPOSITIONS AND METHODS FOR TREATING DEPRESSIONJune 2021April 2025Abandon4610NoNo
174166821H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASESJune 2021November 2025Allow5321YesNo
17414478PYRIDYLOXY CARBOXYLATE DERIVATIVE, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOFJune 2021June 2025Allow4811YesNo
17311212QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTSJune 2021October 2024Allow4001YesNo
17337077FORMULATIONS FOR PERSONALIZED METHODS OF TREATMENTJune 2021September 2024Allow4011YesNo
17291497DOMPERIDONE ANTINEURODEGENERATIVE COMBINATIONS AND USEMay 2021May 2025Abandon4811NoNo
17284429SIMPLE PREPARATION METHOD FOR VABORBACTAMApril 2021October 2024Abandon4201NoNo
17225968FORMULATION FOR PAIN MANAGEMENTApril 2021October 2024Allow4211NoNo
17216357IONIZABLE CATIONIC LIPID FOR RNA DELIVERYMarch 2021January 2026Allow5830YesYes
17279644COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERSMarch 2021January 2026Abandon5721NoNo
17274379METHOD OF PREPARING ACRYLONITRILE DIMERMarch 2021February 2025Allow4730YesNo
17274274COMPOSITION, COMPRISING THIAMINE DERIVATIVE, FOR PREVENTION OR TREATMENT OF HYPERCORTISOLEMIAMarch 2021June 2025Allow5130NoNo
17191310CRYSTALLINE FORMS OF 6-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)NICOTINAMIDEMarch 2021November 2023Allow3300NoNo
17271883METHODS OF TREATING NEURODEGENERATIVE DISEASESFebruary 2021July 2024Abandon4101NoNo
17184776SIGMA RECEPTOR BINDERSFebruary 2021November 2025Abandon5731YesNo
17267513NLRP3 MODULATORSFebruary 2021September 2024Allow4311NoNo
17261267Thioxanthone Derivatives, Composition Comprising the Same and Pattern Forming Method Comprising Said CompositionJanuary 2021April 2025Allow5121YesNo
17260602CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING INFLAMMATORY BOWEL DISEASEJanuary 2021June 2025Abandon5321NoNo
17260682METHODS FOR PURIFYING ISAVUCONAZONIUM SULFATEJanuary 2021May 2025Allow5221NoNo
17260484OPIOID HAPTENS, CONJUGATES, VACCINES, AND METHODS OF GENERATING ANTIBODIESJanuary 2021May 2025Abandon5221NoNo
17259357T-TYPE CALCIUM CHANNEL BLOCKERJanuary 2021October 2024Abandon4511NoNo
17259370ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTIONJanuary 2021September 2024Allow4411YesNo
17258040CRYSTALLINE SALTS OF 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND AMINO ETHYL ESTERSJanuary 2021October 2024Allow4511YesNo
16955510QUINAZOLINE DERIVATIVE AND USE THEREOFDecember 2020April 2025Abandon5811NoNo
17101182NEAR-INFRARED ABSORBING DYE, OPTICAL FILTER, AND IMAGING DEVICENovember 2020August 2024Allow4511NoNo
17050956HIGH CANNABIDIOL CONTAINING CANNABIS CHEMOTYPESOctober 2020May 2024Abandon4301NoNo
16960819PHOSPHOR(N)AMIDATACETAL AND PHOSPH(ON)ATALCETAL COMPOUNDSOctober 2020July 2024Allow4811NoNo
17043763COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASESeptember 2020July 2024Abandon4511NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCANANY, JOHN D.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
0.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MCANANY, JOHN D - Prosecution Strategy Guide

Executive Summary

Examiner MCANANY, JOHN D works in Art Unit 1625 and has examined 40 patent applications in our dataset. With an allowance rate of 60.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner MCANANY, JOHN D's allowance rate of 60.0% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MCANANY, JOHN D receive 1.15 office actions before reaching final disposition. This places the examiner in the 13% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MCANANY, JOHN D is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +59.3% benefit to allowance rate for applications examined by MCANANY, JOHN D. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 71% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 80.0% of cases where such amendments are filed. This entry rate is in the 96% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.